13F-HR: Sanofi Discloses Q4 2025 Equity Holdings in Biotech Firms

Sanofi's latest 13F filing reveals its equity positions in eight biotechnology and pharmaceutical companies as of December 31, 2025, totaling over $310 million.

Summary

• Sanofi, an institutional investment manager, filed a Form 13F Holdings Report for the calendar quarter ended December 31, 2025.
• The report details holdings in 8 different issuers, all held with sole investment discretion.
• The total market value of these holdings is $310,414,825.
• Significant holdings include Inhibrx Biosciences, Inc. (1,157,926 shares valued at $91,476,154), MeiraGTx Holdings plc (12,197,737 shares valued at $96,972,009), and Novavax (6,880,481 shares valued at $46,236,832).
• Other reported holdings include AnaptysBio, Immuneering Corp CLASS A COM, Eledon, Q32 Bio Inc., and MapLight Therapeutics Inc.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it is a standard regulatory disclosure of institutional holdings without explicit performance metrics or strategic shifts detailed by Sanofi.

Positives

• Total reported holdings value reached $310,414,825 as of December 31, 2025, indicating active investment management.

Future Outlook

This Form 13F filing provides a snapshot of Sanofi's equity holdings as of December 31, 2025, and does not contain forward-looking statements or guidance regarding future investment strategies or market outlook.

Management Comments

• The filing includes a representation by Alexandra Roger, Head of Legal Corporate & Finance, stating that the person signing the report is authorized to submit it and that all information contained therein is true, correct, and complete.

Industry Context

StockSavvy.ai notes that Sanofi's disclosed holdings are concentrated in the biotechnology and pharmaceutical sectors, reflecting a strategic focus on life sciences investments. This aligns with broader industry trends where major pharmaceutical companies often invest in or acquire smaller biotech firms to bolster their R&D pipelines and expand therapeutic areas.

Comparison to Industry Standards

• StockSavvy.ai observes that without prior 13F filings or specific investment mandates, a direct comparison of Sanofi's portfolio performance against global benchmarks or peer institutional investors like BlackRock, Vanguard, or other large pharmaceutical companies' venture arms is not feasible based solely on this snapshot. The filing does not provide details on portfolio allocation strategy, performance metrics, or specific investment theses for the listed companies.

Stakeholder Impact

• The filing provides transparency to shareholders and the market regarding Sanofi's equity investment portfolio, potentially influencing investor perception of its strategic focus within the life sciences sector.

Next Steps

• The filing does not explicitly mention future actions, events, or milestones for Sanofi's investment activities beyond the regular quarterly reporting cycle.

Key Dates

Keywords

Sanofi, 13F, holdings, institutional investor, biotechnology, pharmaceuticals, equity, investment, portfolio